Serum hormonal levels in HIV/AIDS infected male subjects on antiretroviral therapy (ART) in Nnewi, Nigeria by Ezeugwunne, IP et al.
 
Available online at http://ajol.info/index.php/ijbcs 
 






© 2012 International Formulae Group. All rights reserved. 
DOI : http://dx.doi.org/10.4314/ijbcs.v6i4.1 
  Original Paper                                                              http://indexmedicus.afro.who.int 
 
Serum hormonal levels in HIV/AIDS infected male subjects on antiretroviral 
therapy (ART) in Nnewi, Nigeria 
 
I.P. EZEUGWUNNE 1, C.C. ONYENEKWE 2, J.E. AHANEKU 2,  
M. IFEANYICHUKWU 3*, S.C.  MELUDU 1, O.W. ONWURAH 4, F.N. OSUJI 5 
 
1Department of Human Biochemistry; College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria. 
2 Department of Chemical Pathology; College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria. 
3 Department of Immunology, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria. 
 4 Heamatology Department; Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. 
5 Immaculate Heart Hospital and Maternity. P.O. Box 29 Nkpor, Anambra State, Nigeria. 





This study was designed to assess the serum hormonal levels (Follicle Stimulating Hormone (FSH), 
Luteinizing Hormone (LH), Testosterone, Estrogen, Progesterone, Prolactin and Cortisol) in symptomatic 
HIV/AIDS male subjects on ART. A total of 411 participants aged between 17 and 58 (43 ±10) years were 
randomly recruited for the study. The participants were staged and grouped as follows: symptomatic 
HIV/AIDS male subjects on ART (n= 139), symptomatic HIV/AIDS male subjects not on ART (n= 136) and 
HIV seronegative subjects (n= 136). Blood samples were collected from the participants for the determination 
of HIV status by immunochromatography and HIV confirmation by Western Blot. Enzyme Linked 
Immunosorbent assay (ELISA) was used to assay for FSH, LH, Testosterone, Estrogen, Progesterone, Prolactin 
and Cortisol levels. Their results showed significant rise in FSH, LH in HIV seropositive participants on ART 
compared respectively to those not on ART and the HIV seropositive subjects (p< 0.05). On the other hand, the 
Estrogen, Progesterone, Prolactin and Cortisol were all aised in symptomatic HIV seropositive participants not 
on ART compared respectively to the symptomatic HIV seroposive on ART and the HIV seronegative groups 
(p< 0.05). The testosterone levels significantly decreased in both symptomatic HIV infected subjects on ART 
and those not on ART compared with the HIV seronegative controls (p< 0.05). The relevance of HIV infection 
on the serum hormonal status is that HIV infection causes hypogonadism as well as primary testicular failure in 
symptomatic HIV participants not on ART. Also, HIV infection causes hyperprolactinaemia, 
hyperprogesteronaemia and hypercortisolism in sympto a ic HIV participants not on ART.  
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A number of disease conditions have 
been reported to affect endocrine organs. The 
infiltration of endocrine glands by tumor or 
infections has been observed (WHO, 2006). 
Endocrine manifestations of Human 
Immunodeficiency Virus (HIV) infection has 
been reported to include both pathological 
changes and disturbances in function. The 
endocrine manifestations may be as a result of 
direct effect of the HIV infection on 
glands.Such glands affected by HIV infection 
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include the liver (Houssat et al., 1990), 
adrenal (Pransanthai et al., 2007; Meena et al., 
2011) and gonads (Roof and Hall, 2000). 
Cardiovascular disorders have also been 
implicated in HIV infection (Sarivastava et 
al., 2004), especially in advanced stage of the 
infection (Cohen et al., 2005) 
HIV is transmitted via exposure to 
contaminated body fluids, such as blood 
(Baggaley et al., 2006) or breast milk 
(Salazar-Gonzalez et al., 2011). Possible 
routes of transmission include blood 
transfusions (Dwyre et al., 2011), intravenous 
drug use (Raguin et al., 2011) and unprotected 
sexual intercourse (Hariri and Mekenna, 
2007). 
As HIV continues to survive and 
replicate within its human host, it eventually 
weakens the immune system; this leaves the 
infected individual susceptible to 
opportunistic infections and neoplasms which 
have been observed to have affected the 
endocrine system in patients with AIDS 
(Onyancha and Ocholla, 2009). Also, patients 
treated with long-term antiretroviral therapy 
usually develop lipodystrophy, insulin 
resistance, and increased cardiovascular risk.
Regrettably, these drug-induced conditions 
diminish patients’ quality of life and 
contribute to an increased rate of 
cardiovascular events and diabetes (Palios et 
al., 2011).  
Most HIV-infected persons have been 
reported to have elevated basal Cortisol levels 
(Corcoran and Grinspoon, 1999). Meena et 
al., (2011) demonstrated a high incidence of 
endocrine dysfunction in HIV infected patient. 
They also observed high incidence of gonadal 
dysfunction in those subjects. Low 
Testosterone levels with elevated LH and FSH 
have also been documented in patients with 
symptomatic or advanced HIV disease, 
thereby suggesting primary testicular failure 
in this grouu8p (Villette et al., 1990). 
Leserman (2008) has revealed that depression, 
stressful events and trauma might affect HIV 
disease progression and Cortisol being a 
stressful hormone might be increased in HIV 
disease. 
However, since most of the findings on 
the effect of HIV on the endocrine system 
documented were not observed in Nigeria, 
hence, the design of this study was to assess 
the effect of HIV infection in some endocrine 
hormones in symptomatic HIV infected 
subjects on ART in Nigeria to see if there will 
be differences in the results. 
 
MATERIALS AND METHODS 
Subjects 
A total of 411 male participants aged 
between 17 and 68 (43 ±10) years were 
randomly recruited at both Antiretroviral 
Therapy (ART) Clinic and Voluntary 
Counseling and Testing (VCT) Centre in 
Nnamdi Azikiwe University Teaching 
Hospital (NAUTH), Nnewi, Nigeria. Based on 
World Health Organisation (WHO) criteria for 
HIV staging, the participants were staged and 
grouped as follows: symptomatic HIV stage 
11 subjects on ART (N=139). Lamivudine, 
150 mg twice daily, Stavudine, 40mg twice 
daily and Nevirapine, 200 mg twice daily: this 
was administered to the symptomatic HIV 
stage 11 subjects on ART. Symptomatic HIV 
subjects not on ART (n= 136) and HIV 
seronegative subjects (n= 136). The subjects 
were given informed consent, while the study 
design was approved by the ethical committee 
of Nnamdi Azikiwe University Teaching 
Hospital, Nnewi, Nigeria. 5 ml of blood 
sample were collected from each of the 
participant in the groups. The participants 
were screened for HIV infection using 
Immunoassay and Immunochromatographic 
method. The serum was used for the 
estimation of FSH, LH, Testosterone, 
Estrogen, Progesterone, Prolactin and Cortisol 
levels. The serum samples were stored at -20 
°C until analyzed. 
 
Detection of antibodies to HIV-1 and HIV-2 
in human plasma 
Two different methods were used, 
namely, Abbott determine TM HIV -1 and 
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HIV-2 kit, which is an in-vitro visually read 
immunoassay (Abbott Japan Co.Ltd.Tokyo, 
Japan) and HIV-1 and 2 STAT-PAK Assay 
kit, which is an Immunochromatographic test 
for the quantitative detection of antibodies to 
HIV-1 and HIV-2 in Human plasma 
(CHEMBIO Diagnostic system, Inc, New 
York, USA). For the Abbott determine TM 
HIV -1 and HIV-2 kit, the procedure 
described by the manufacturer were used for 
the analysis. Briefly, 50 µl of participant 
serum samples separated from the 
corresponding whole blood samples in EDTA 
were applied to the appropriately labeled 
sample pad. After 15 minutes but not more 
than 60 minutes of sample application, the 
result was read. This method has inherent 
quality control that validates the results. For 
the Immunochromatographic method for HIV 
-1 and HIV-2, the procedure described by the 
manufacturer was used for the analysis. In 
brief, 5 ml of participant’s plasma were 
dispensed into the sample well in the 
appropriately labeled sample pad. Three drops 
of the buffer supplied by the manufacturer 
were added into the appropriately labeled 
sample pad. The results of the test were read 
at 10 minutes after the addition of the running 
buffer. This method has inherent quality 
control and validates the results. 
CD4+ T CELL Count by Flow 
Cytometry 200 ml EDTA whole blood was 
collected into PARTEC test tubes (Rohren 
tube). Then 20 µl ofCD4+ T antibodies were 
added into the tube. The contents were mixed 
and incubated in the dark for15 minutes at 
roomtemperature. 800 ml of CD4 buffer were 
gently added into the mixture and mixed 
gently. Then, the Partec tube was plugged on 
the Cyflow counter and the CD4+ T cells were 
displayed as peaks and interpreted as figures. 
 
Estimation of FSH by Randox Laboratories 
Limited, U.K 
Serum FSH was estimated by Enzyme 
Linked Immunosorbent assay (ELISA). The 
procedure were as described by the 
manufacturer of the kit (Randox Laboratories 
Limited, UK): 50 µl of serum sample were 
added to appropriately labeled microtitre wells 
and 100 µl Enzyme conjugated detection 
antibody were also added to the wells. The 
same procedures were performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at room 
temperature for 45 minutes. The wells were 
washed 3 times with deionized water to 
remove unbound antibodies. 100 µl 
tetramethylbenzidine (TMB) reagent were 
added and well incubated at room temperature 
for 20 minutes for the colour to develop. 
100µl of hydrochloric acid (HCL) were added 
to the various wells to stop further 
development of colour. Absorbance was read 
at 450nm using ELISA machine and 
deionized water served as blank. The test and 
control samples concentrations were 
extrapolated from the standard curve. The 
standard curve was plotted from the 
absorbance values and concentrations of series 
of FSH standards (0, 5, 15, 50, 100 and 200 
miu/ml) provided by the manufacturer of the 
kit. 
 
Estimation of LH by Randox Laboratories 
Limited, U.K 
Serum LH was estimated by Enzyme 
Linked Immunosorbent assay (ELISA). The 
procedure was as described by the 
manufacturer of the kit (Randox Laboratories 
Limited, UK): 50 µl of serum sample were 
added to appropriately labeled microtitre wells 
and 100 µl Enzyme conjugated detection 
antibody were also added to the wells. The 
same procedure was performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at room 
temperature for 45 minutes. The wells were 
washed 3 times with deionized water to 
remove unbound antibodies. 100 µl TMB 
reagents were added and well incubated in the 
dark for 20 minutes for the colour to develop. 
100 µl of HCL were added to the various 
wells to stop further development of colour. 
Absorbance was read at 450 nm using ELISA 
machine and deionized water served as blank. 
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The test and control samples concentrations 
were extrapolated from the standard curve. 
The standard curve was plotted from the 
absorbance values and concentrations of series 
of FSH standards (0, 5, 15, 50, 100 and 200 
miu/ml) provided by the manufacturer of the 
kit. 
 
Estimation of Testosterone by Randox 
Laboratories Limited, U.K 
Serum Testosterone was estimated by 
Enzyme Linked Immunosorbent assay 
(ELISA). The procedure was as described by 
the manufacturer of the kit (Randox 
Laboratories Limited, UK): 10 µl of serum 
sample were added to appropriately labeled 
microtitre wells and 100 µl Enzyme 
conjugated detection antibody were also 
added to the wells. Also, 5µl of rabbit anti-
Testosterone reagent were added in each well. 
The same procedure was performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at 37 °C 
for 90 minutes. The wells were washed 3 
times with deionized water to remove 
unbound antibodies. 100 µl TMB reagent 
were added and well incubated at room 
temperature for 20 minutes for the colour to 
develop. 100 µl of HCL were added to the 
various wells to stop further development of 
colour. Absorbance was read at 450 nm using 
ELISA machine and deionized water served 
as blank. The test and control samples 
concentrations were extrapolated from the 
standard curve. The standard curve was 
plotted from the absorbance values and 
concentrations of series of FSH standards (0, 
0.1, 0. 5, 2, 6 and 18 ng/ml) provided by the 
manufacturer of the kit. 
 
Estimation of Estradiol by Randox 
Laboratories Limited, U.K 
Serum Estradiol was estimated by 
Enzyme Linked Immunosorbent assay 
(ELISA). The procedure was as described by 
the manufacturer of the kit (Randox 
Laboratories Limited, UK): 25 µl of serum 
sample were added to appropriately labeled 
microtitre wells and 100 µl Enzyme 
conjugated detection antibody were also 
added to the wells. Also, 5 µl of rabbit anti- 
Estradiol reagent were added in each well. 
The same procedure was performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at 37 °C 
for 90 minutes. The wells were washed 3 
times with deionized water to remove 
unbound antibodies. 100 µl TMB reagent 
were added and well incubated at room 
temperature for 20 minutes for the colour to 
develop. 100 µl of HCL were added to the 
various wells to stop further development of 
colour. Absorbance was read at 450nm using 
ELISA machine and deionized water served 
as blank. The test and control samples 
concentrations were extrapolated from the 
standard curve. The standard curve was 
plotted from the absorbance values and 
concentrations of series of FSH standards (0, 
10, 30, 100 and 1000 pg/ml) provided by the 
manufacturer of the kit. 
 
Estimation of Progesterone by Randox 
Laboratories Limited, U.K 
Serum Progesterone was estimated by 
Enzyme Linked Immunosorbent assay 
(ELISA). The procedure was as described by 
the manufacturer of the kit (Randox 
Laboratories Limited, UK); 25 µl of serum 
sample were added to appropriately labeled 
microtitre wells and 100 µl Progesterone 
Enzyme horseradish peroxidase conjugate 
reagent were added to the wells. Also, 50 µl of 
rabbit anti-Progesterone reagent was added in 
each well. The same procedure was performed 
for the standard as well as HIV negative 
control serum samples. They were incubated 
at room temperature for 90 minutes. The wells 
were washed 3 times with deionized water to 
remove unbound antibodies. 100 µl TMB 
reagent were added and well incubated at 
room temperature for 20 minutes for the 
colour to develop. 100 µl of HCL was added 
to the various wells to stop further 
development of colour. Absorbance were read 
at 450 nm using ELISA machine and 
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deionized water served as blank. The test and 
control samples concentrations were 
extrapolated from the standard curve. The 
standard curve was plotted from the 
absorbance values and concentrations of series 
of FSH standards (0, 0.5, 3, 10, 25 and 50 
ng/ml) provided by the manufacturer of the 
kit. 
 
Estimation of Prolactin by Randox 
Laboratories Limited, U.K 
Serum Prolactin was estimated by 
Enzyme Linked Immunosorbent assay 
(ELISA). The procedure was as described by 
the manufacturer of the kit (Randox 
Laboratories Limited, UK); 50 µl of serum 
sample were added to appropriately labeled 
microtitre wells and 100 µl Enzyme conjugate 
reagent were also added to the wells. The 
same procedure was performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at room 
temperature for 45 minutes. The wells were 
washed 3 times with deionized water to 
removed unbound antibodies. 100 µl TMB 
reagents were added and well incubated at 
room temperature for 20 minutes for the 
colour to develop. 100 µl of HCL were added 
to the various wells to stop further 
development of colour. Absorbance was read 
at 450 nm using ELISA machine and 
deionized water served as blank. The test and 
control samples concentrations were 
extrapolated from the standard curve. The 
standard curve was plotted from the 
absorbance values and concentrations of series 
of FSH standards (0, 5, 15, 50, 100 and 200 
ng/ml) provided by the manufacturer of the 
kit. 
 
Estimation of Cortisol byRandox 
Laboratories Limited, U.K 
Serum Cortisol was estimated by 
Enzyme Linked Immunosorbent assay 
(ELISA). The procedure were as described by 
the manufacturer of the kit (Randox 
Laboratories Limited, UK): 20 µl of serum 
sample were added to appropriately labeled 
microtitre wells and 200 µl Enzyme conjugate 
reagent were also added to the wells. The 
same procedure was performed for the 
standard as well as HIV negative control 
serum samples. They were incubated at room 
temperature for 60 minutes. The wells were 
washed 3 times with deionized water to 
remove unbound antibodies. 100 µl TMB 
reagent were added and well incubated at 
room temperature for 20 minutes for the 
colour to develop. 100µl of HCL were added 
to the various wells to stop further 
development of colour. Absorbance was read 
at 450nm using ELISA machine and 
deionized water served as blank. The test and 
control samples concentrations were 
extrapolated from the standard curve. The 
standard curve was plotted from the 
absorbance values and concentrations of series 
of FSH standards (0, 20, 50, 100, 200, 400 
and 800 ng/ml) provided by the manufacturer 
of the kit. 
 
Statistical analysis 
The result of the analysis was 
statistically analysed. Students’t-test and one 
way analysis of variance (ANOVA) were used 
to compare means. The analysis was 
performed with the use of Statistical Package 
for Social Sciences (SPSS) statistical software 
package, version 13.0.  P <0.05 was 
considered statistically significant. 
 
RESULTS 
The result of analysis of variance 
showed that the serum levels of FSH, LH, 
Testosterone, Estrogen, Progesterone, 
Prolactin and Cortisol were significantly 
different amongst the group (F= 15.56, 10.40, 
38.40, 11.34, 27.77, 23.22 and 59.96) 
(p<0.05) respectively. 
The result of independent student’s t-
test showed that serum FSH (miu/ml)  level 
was significantly higher in HIV seropositive 
participants on ART 15.21 (±7.70) compared 
with HIV seropositive participants not on 
ART 12.63 (±8.57) (p<0.05). Also, the serum 
FSH level in HIV seropositive participants on 
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ART HIV seropositive participants on ART 
was significantly higher than the value in HIV 
seronegative participants 10.03 (±6.67) 
(p<0.05). Similarly, the serum FSH value in 
HIV seropositive participants not on ART 
12.63 (±8.57) was significantly higher than 
the value in HIV seronegative participants 
10.03 (±6.67) (p<0.05). 
The result of independent student’s t-
test showed that serum LH (miu/ml)  level 
was significantly higher in HIV seropositive 
participants on ART 13.38 (±7.19) compared 
with HIV seropositive participants not on 
ART 11.16 (±7.70) (p<0.05). Similarly, the 
serum LH level in HIV seropositive 
participants on ART HIV 13.38(±7.19) was 
significantly higher than the value in HIV 
seronegative participants 9.44 (±6.61) 
(p<0.05). Also, the serum LH value in HIV 
seropositive participants not on ART 11.16 
(±7.70) was significantly higher than the value 
in HIV seronegative participants 9.44 (±6.61) 
(p<0.05). 
The mean (±SD) of serum Testosterone 
(ng/ml)   levels in HIV seropositive 
participants on ART 2.68 (±2.04) was 
significantly lower compared with the 
corresponding value in HIV seronegative 
participants 4.74 (±1.83) (p<0.05). Again, the 
mean (±SD) of serum Testosterone value was 
significantly lower in HIV seropositive 
participants not on ART 2.91 (±6.21) 
compared with the value in HIV seronegative 
participants 4.74 (±1.83) (p<0.05). However, 
no significant mean differences was observed 
between HIV seropsitive participants with and 
without ART (p<0.05). 
The mean (±SD) of serum Estrogen 
(pg/ml) level in HIV seropositive participants 
on ART 55.12 (±36.89) showed significantly 
higher value compared with HIV seronegative 
group 32.81 (±20.92) (p<0.05). Also, the 
mean (±SD) Estrogen (pg/ml)  value observed 
in HIV seropositive participants not on ART 
60.73 (±22.72) was significantly higher 
compared with the value in HIV seronegative 
group 32.81 (±20.92) (p<0.05). However, the 
mean (±SD) Estrogen (pg/ml) showed similar 
values in HIV seropositive participants on 
ART 55.12 (±36.89) and in HIV seropositive 
participants not on ART 60.73 (±22.72) 
(p<0.05). 
The mean (±SD) of serum Progesterone 
(ng/ml) level was significantly lower in HIV 
seropositive participants on ART 1.93 (±1.54) 
compared with the value in HIV seropositive 
participants not on ART 2.34 (±1.51) 
(p<0.05). Also, the mean (±SD) of serum 
Progesterone (ng/ml) level was significantly 
higher in HIV seropositive participants on 
ART 1.93 (±1.54) compared with the value in 
HIV seronegative group 1.11 (±1.06) 
(p<0.05). 
The mean (±SD) of serum Prolactin 
(ng/ml) level was significantly lower in HIV 
seropositive participants on ART 6.63 (±4.36) 
compared with the value in HIV seropositive 
participants not on ART 9.83 (±4.32) 
(p<0.05). Similarly, significantly lower in 
mean (±SD) Prolactin (ng/ml) value was 
observed in HIV seropositive participants on 
ART 6.63 (±4.36) compared with HIV 
seronegative group 8.93 (±3.31) (p<0.05). 
However, no significant mean difference in 
serum Prolactin (ng/ml) was observed in HIV 
seropositive participants not on ART 9.83 
(±4.32) compared with HIV seronegative 
group 8.93 (±3.31) (p<0.05). 
The mean (±SD) of serum Cortisol 
(ng/ml) level was significantly lower in HIV 
seropositive participants on ART 127.98 
(±69.90) compared with the value in HIV 
seropositive participants not on ART 238.63 
(±129.12) (p<0.05). Also, the mean (±SD) of 
serum Cortisol (ng/ml) level was significantly 
higher in HIV seropositive participants not on 
ART 238.63 (±129.12) compared with HIV 
seronegative group 138.86 (±64.28) (p<0.05). 
However, no significant mean difference in 
serum Cortisol (ng/ml) was observed in HIV 
seropositive participants on ART 127.98 
(±69.90) compared with HIV seronegative 
group 138.86 (±64.28) (p<0.05) (Table 1). 
























Symptomatic HIV/AIDS on ART (n=139) 15.21 ± 7.70 13.38 ± 7.19 2.68 ± 2.04 55.12 ± 3.89 1.93 ± 1.54 6.63 ±4.36 127.98 ± 69.90 
Symptomatic HIV/AIDS not on ART (n=139) 12.62 ± 8.57 11.16 ± 7.70 2.91 ± 6.21 60.73 ± 22.72 2.34 ± 1.51 9.83 ± 4.32 238.63 ± 129.12 
HIV Seronegative Control (n=136) 10.03 ± 6.67 9.44 ± 6.61 4.74 ±1.83 32.83 ± 20.92 1.11 ± 1.06 8.93 ± 3.31 138.86 ± 64.28 
FP 15.56 10.4 38.4 11.34 27.77 23.22 59.96 
 <0.05 >0.05 >0.05 >0.05 >0.05 <0.05 <0.05 
TIpa <0.05 <0.05 >0.05 >0.05 <0.05 <0.05 <0.05 
TIpb <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 >0.05 
TIpc <0.05 <0.05 <0.05 <0.05 <0.05 >0.05 <0.05 
Fp  = HIV on ART subjects, HIV not on ART subjects and HIV seronegative control  group compared using ANOVA;  
TIpa = HIV on ART subjects compared with HIV not on ART subjects (using student’s t-test); 
TIpb = HIV on ART subjects compared with HIV seronegativecontrol  subjects (using student’s t-test); 
TIpc = HIV not on ART subjects compared with HIV seronegativecontrol  subjects (using student’s t-test). 
 




The study revealed a significant higher 
mean values in serum FSH and LH levels in 
symptomatic HIV seropositive participants on 
ART than in the HIV seropositive 
participants. The implication of this finding 
could be that HIV infection has a stimulatory 
effect on the release of these hormones from 
the pituitary. Also, the implication of elevated 
serum FSH and LH levels in symptomatic 
HIV seropositive participants signify that the 
HIV infection has a hypogonadal effect on the 
testicles. This finding is in the support of the 
report that elevated serum FSH and LH levels 
have been implicated in HIV infection with 
hypogonadism (Purohit et al., 2004; 
Selimeryer and Grunfeld, 2006). 
In this study, the serum Testosterone 
level was significantly lower in symptomatic 
HIV participants. Also, the serum Estrogen 
value was significantly higher in symptomatic 
HIV participants. This implies that the HIV 
infection might have interfere with the 
gonadal Tesotosterone synthesis or it has 
favors the formation of Estrogen from 
Testosterone which also known as Estrogenic 
effect hence the low serum Testosterone 
observed in these subjects. Estrogenic effect is 
a peripheral conversion of Testosterone to 
Estrogen by Aromatase and Enolase 
(Meinhardt and Mullis, 2002). 
Nevertheless, low Testosterone has 
been implicated in hypogonadism in 
asymptomatic HIV infection (Roof and Hall, 
2000).  Low serum Testosterone levels with 
elevated LH and FSH levels have also been 
reported in patients with symptomatic or 
advanced HIV disease, indicating primary 
testicular failure (Meena et al., 2011).  
The serum Prolactin level was also 
observed to be elevated in symptomatic HIV 
participants not on ART. The observed 
increase in Prolactin value might be as a result 
of the disease burden on the pituitary, thereby 
causing an increased stimulation and secretion 
of Prolactin into the circulation. 
Hyperprolactinaemia has been linked to 
impotence and loss of libido (Gregg et al., 
1997). Also, hyperprolactinaemia has been 
linked with gynaecomasia in HIV subjects 
(Biglia et al., 2004). The reduced Prolactin 
level observed on those on drug might be as a 
result of health recovery from ART treatment 
(Burgoyne and Tan, 2008; Dybul et al., 2002). 
This study also observed that the serum 
Progesterone and Cortisol level were 
significantly high in symptomatic HIV 
participants. These values were significantly 
higher in symptomatic HIV participants not 
on ART. The implication might be that the 
HIV infection retards the synthesis of 
Progesterone. Cortisol is synthesized from 
Progesterone through glucocorticoid pathway 
(John et al., 2007). So, the elevated serum 
Cortisol observed in symptomatic HIV 
participants not on ART might be as a result 
of stress impact from the HIV infection. Other 
researchers have reported hypercortisolism in 
HIV infected subjects as a result of stress 
impact from the disease (Leserman, 2008; 
Meena et al., 2011). Also, Cortisol as stress 
steroid hormone is released in response to 
stress or anxiety (Gropper et al., 2008). 
Indeed, Unachukwu et al. (2009) observed 
that it was virtually every endocrine organ is 
involved in the course of HIV infection just as 
was seen in this study. 
 
Conclusion 
The present study thus concludes that 
HIV infection causes hypogonadism as well 
as primary testicular failure in symptomatic 
HIV participants not on ART as evidenced by 
the elevated levels of serum FSH, LH and low 
Testosterone. Also, HIV infection causes 
hyperprolactinaemia, hyperprogesteronaemia 
and hypercortisolism in symptomatic HIV 
participants not on ART. Hence, this study 
suggests that HIV infection causes endocrine 
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